Granted Patent
B2
US 12,492,434 · App. 17/308,958 · Granted Dec 9, 2025
Methods and systems for analyzing nucleic acid molecules
Inventors:
David M. Kurtz (San Francisco, CA); Maximilian Diehn (San Carlos, CA); Arash Ash Alizadeh (San Mateo, CA)
C12Q1/6886C12N15/1089C12Q1/6869C12Q1/6874G16B20/00G16B20/10G16B20/20G16B30/00G16B30/10G16B35/20G16B40/00G16H10/40G16H20/10G16H50/20G16H50/30G16H50/70G16H70/60C12Q2600/112C12Q2600/156C12Q2600/158G01N2800/7028G16H10/60
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.
Claims (41)
1 . A computer-implemented method comprising:
(a) obtaining, by a computer system, sequence read data derived from at least 10,000 cell-free nucleic acid molecules obtained or derived from a subject;
(b) processing, by the computer system, the sequence read data and thereby (1) identifying one or more cell-free nucleic acid molecules of the at least 10,000 cell-free nucleic acid molecules as phased variant-containing cell-free nucleic acid molecules, wherein each of the one or more identified phased variant-containing cell-free nucleic acid molecules comprises a plurality of phased variants relative to a reference genomic sequence of at least 100 kb in length that are separated by at least one nucleotide, wherein identifying the one or more cell-free nucleic acid molecules as phased-variant containing cell-free nucleic acid molecules comprises aligning reads corresponding to each of the at least 10,000 cell-free nucleic acid molecules to the reference genomic sequence, and (2) identifying one or more insertions or deletions (indels) relative to the reference genomic sequence of at least 100 kb in length; and
(c) analyzing, by the computer system, the identified one or more cell-free nucleic acid molecules and the one or more indels to determine a condition of the subject, wherein the condition is a cancer.
2 . The method of claim 1 , wherein the one or more cell-free nucleic acid molecules are identified with a limit of detection of less than 1 out of 1,000,000 observations from the sequence read data.
3 . The method of claim 1 , wherein the sequence read data is generated based at least in part on nucleic acid amplification or polymerase chain reaction.
4 . The method of claim 1 , wherein the sequence read data is generated based at least in part on amplicon sequencing.
5 . The method of claim 1 , wherein the sequence read data is generated based at least in part on next-generation sequencing (NGS) or non-hybridization-based NGS.
6 . The method of claim 1 , wherein the sequence read data is generated without use of molecular barcoding of at least a portion of the plurality of cell-free nucleic acid molecules.
7 . The method of claim 1 , wherein the sequence read data is obtained without use of sample barcoding of at least a portion of the plurality of cell-free nucleic acid molecules.
8 . The method of claim 1 , wherein the sequence read data is obtained without in silico removal or suppression of (i) background error or (ii) sequencing error.
9 . The method of claim 1 , wherein the reference genomic sequence of at least 100 kb in length comprises at least a portion of hg19 human genome, hg18 human genome, hg17 human genome, hg16 human genome, or hg38 human genome.
10 . The method of claim 1 , wherein the reference genomic sequence of at least 100 kb in length is the genome from the subject.
11 . The method of claim 1 , wherein the at least 10,000 cell-free nucleic acid molecules are derived from serum or plasma of the subject.
12 . A computer program product comprising a non-transitory computer-readable medium having computer-executable code encoded therein, the computer-executable code adapted to be executed to implement a method comprising:
(a) obtaining, by a computer system, sequence read data derived from at least 10,000 cell-free nucleic acid molecules obtained or derived from a subject;
(b) processing, by the computer system, the sequence read data and thereby (1) identifying one or more cell-free nucleic acid molecules of the at least 10,000 cell-free nucleic acid molecules as phased variant-containing cell-free nucleic acid molecules, wherein each of the one or more of the identified phased variant-containing cell-free nucleic acid molecules comprises a plurality of phased variants relative to a reference genomic sequence of at least 100 kb in length that are separated by at least one nucleotide, wherein identifying the one or more cell-free nucleic acid molecules as phased-variant containing cell-free nucleic acid molecules comprises aligning reads corresponding to each of the at least 10,000 cell-free nucleic acid molecules to the reference genomic sequence of at least 100 kb in length, and (2) identifying one or more insertions or deletions (indels) relative to the reference genomic sequence of at least 100 kb in length; and
(c) analyzing, by the computer system, the identified one or more cell-free nucleic acid molecules and the one or more indels to determine a condition of the subject, wherein the condition is a cancer.
13 . A method comprising:
(a) obtaining, by a computer system, sequence read data derived from at least 10,000 cell-free nucleic acid molecules obtained or derived from a subject who has received an organ or tissue transplant;
(b) processing, by the computer system, the sequence read data and thereby identifying one or more cell-free nucleic acid molecules of the at least 10,000 cell-free nucleic acid molecules as phased variant containing cell-free nucleic acid molecules, wherein each of the one or more identified phased variant-containing cell-free nucleic acid molecules comprises a plurality of phased variants relative to a reference genomic sequence of at least 100 kb in length that are separated by at least one nucleotide, wherein identifying the one or more cell-free nucleic acid molecules as phased-variant containing cell-free nucleic acid molecules comprises aligning reads corresponding to each of the at least 10,000 cell-free nucleic acid molecules to the reference genomic sequence of at least 100 kb in length; and
(c) analyzing, by the computer system, the identified one or more cell-free nucleic acid molecules to determine a presence, an absence, or an extent of transplant rejection of the subject.
14 . The method of claim 13 , wherein (b) further comprises identifying one or more insertions or deletions (indels) relative to the reference genomic sequence of at least 100 kb in length, and wherein (c) further comprises determining the presence, the absence, or the extent of transplant rejection of the subject based at least in part on the identified one or more indels.
15 . The method of claim 13 , wherein the one or more cell-free nucleic acid molecules are identified with a limit of detection of less than 1 out of 1,000,000 observations from the sequence read data.
16 . The method of claim 13 , wherein the sequence read data is generated based at least in part on nucleic acid amplification or polymerase chain reaction.
17 . The method of claim 13 , wherein the sequence read data is generated based at least in part on amplicon sequencing.
18 . The method of claim 13 , wherein the sequence read data is generated based at least in part on next-generation sequencing (NGS) or non-hybridization-based NGS.
19 . The method of claim 13 , wherein the sequence read data is generated without use of molecular barcoding of at least a portion of the plurality of cell-free nucleic acid molecules.
20 . The method of claim 13 , wherein the sequence read data is obtained without use of sample barcoding of at least a portion of the plurality of cell-free nucleic acid molecules.
21 . The method of claim 13 , wherein the sequence read data is obtained without in silico removal or suppression of (i) background error or (ii) sequencing error.
22 . The method of claim 13 further comprising:
(d) identifying the subject for treatment of the transplant rejection, based at least in part on the presence or the extent of the transplant rejection determined in (c); and
(e) subjecting the subject to the treatment based on the identifying in (d).
23 . The method of claim 13 , wherein the at least 10,000 cell-free nucleic acid molecules are donor-derived cell-free nucleic acid molecules.
24 . The method of claim 13 , wherein the reference genomic sequence of at least 100 kb in length comprises at least a portion of hg19 human genome, hg18 human genome, hg17 human genome, hg16 human genome, or hg38 human genome.
25 . The method of claim 22 , wherein the treatment is selected from the group consisting of an immunosuppressive drug, an antibody-based treatment, a blood transfer, a marrow transplant, a gene therapy, a transplant removal, and a re-transplant procedure.
26 . The method of claim 25 , wherein the immunosuppressive drug is selected from the group consisting of a corticosteroid, a calcineurin inhibitor, an anti-proliferative, and an mTOR inhibitor.
27 . The method of claim 25 , wherein the antibody-based treatment is selected from the group consisting of a monoclonal anti-IL-2Rα receptor antibody, a polyclonal anti-T-cell, and a monoclonal anti-CD20 antibody.
28 . The method of claim 13 , further comprising monitoring the subject for the presence, the absence, or the extent of the transplant rejection.
29 . The method of claim 13 , wherein the reference genomic sequence of at least 100 kb in length is the genome from the subject.
30 . The method of claim 13 , wherein the at least 10,000 cell-free nucleic acid molecules are derived from serum or plasma of the subject.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 12, 2022
From: KURTZ, DAVID M.; DIEHN, MAXIMILIAN; ALIZADEH, ARASH ASH
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 059578/0491 →
Continuity (3)
Continuation In Part
PCTUS2020059526
· Nov 6, 2020
Provisional Application
62931688
· Nov 6, 2019
References Cited (327)
US 5804396A
· Plowman
· 1998
[cited by applicant]
US 6171856B1
· Thigpen et al.
· 2001
[cited by applicant]
US 8105769B2
· Bell et al.
· 2012
[cited by applicant]
US 8318433B2
· Brenner
· 2012
[cited by applicant]
US 8580497B2
· Stratton et al.
· 2013
[cited by applicant]
US 8722368B2
· Casbon et al.
· 2014
[cited by applicant]
US 8741606B2
· Casbon et al.
· 2014
[cited by applicant]
US 8835358B2
· Fodor et al.
· 2014
[cited by applicant]
US 9035036B2
· Bell et al.
· 2015
[cited by applicant]
US 9340830B2
· Lipson et al.
· 2016
[cited by applicant]
US 9598731B2
· Talasaz
· 2017
[cited by applicant]
US 9752188B2
· Schmitt et al.
· 2017
[cited by applicant]
US 9834822B2
· Talasaz
· 2017
[cited by applicant]
US 9840743B2
· Talasaz
· 2017
[cited by applicant]
US 9850523B1
· Chudova et al.
· 2017
[cited by applicant]
US 9902992B2
· Talasaz et al.
· 2018
[cited by applicant]
US 9920366B2
· Eltoukhy et al.
· 2018
[cited by applicant]
US 20020015718A1
· Kruse et al.
· 2002
[cited by applicant]
US 20130210645A1
· Volgelstein et al.
· 2013
[cited by applicant]
US 20140296081A1
· Diehn et al.
· 2014
[cited by applicant]
US 20150376700A1
· Schnall-Levin et al.
· 2015
[cited by applicant]
US 20160032396A1
· Diehn et al.
· 2016
[cited by applicant]
US 20180265928A1
· Schnall-Levin et al.
· 2018
[cited by applicant]
US 20200131505A1
· Green et al.
· 2020
[cited by applicant]
US 20210172022A1
· Kurtz et al.
· 2021
[cited by applicant]
US 20220251664A1
· Kurtz et al.
· 2022
[cited by applicant]
US 20220389518A1
· Kurtz et al.
· 2022
[cited by applicant]
US 20230124070A1
· Kurtz et al.
· 2023
[cited by applicant]
US 20230183816A1
· Kurtz et al.
· 2023
[cited by applicant]
US 20230250485A1
· Kurtz et al.
· 2023
[cited by applicant]
US 20240105281A1
· Chabon et al.
· 2024
[cited by applicant]
US 20240175088A1
· Kurtz et al.
· 2024
[cited by applicant]
CN 105518151A
· 2016
[cited by applicant]
CN 106536756A
· 2017
[cited by applicant]
CN 107208156A
· 2017
[cited by applicant]
CN 107223159A
· 2017
[cited by applicant]
CN 108368542A
· 2018
[cited by applicant]
CN 108624668A
· 2018
[cited by applicant]
CN 109337983A
· 2019
[cited by applicant]
CN 113383085A
· 2021
[cited by applicant]
CN 115443341A
· 2022
[cited by applicant]
EP 3561075A1
· 2019
[cited by applicant]
EP 4110397A1
· 2023
[cited by applicant]
EP 4110957A2
· 2023
[cited by applicant]
EP 4334476A1
· 2024
[cited by applicant]
GB 2595193A
· 2021
[cited by applicant]
KR 20220145891A
· 2022
[cited by applicant]
KR 20220157976A
· 2022
[cited by applicant]
WO WO2014151117A1
· 2014
[cited by applicant]
WO WO2015188192A2
· 2015
[cited by applicant]
WO WO2016040901A1
· 2016
[cited by applicant]
WO WO2016049993A1
· 2016
[cited by applicant]
WO WO2017070123A1
· 2017
[cited by applicant]
WO WO2017100441A1
· 2017
[cited by applicant]
WO 2017161175A1
· 2017
[cited by applicant]
WO WO2018195483A1
· 2018
[cited by applicant]
WO WO2018231818A1
· 2018
[cited by applicant]
WO WO2020154682A2
· 2020
[cited by applicant]
WO WO2020204674A2
· 2020
[cited by applicant]
WO WO2021003485A1
· 2021
[cited by applicant]
WO 2021092476A1
· 2021
[cited by applicant]
WO WO2021173722A2
· 2021
[cited by applicant]
WO WO2021173724A1
· 2021
[cited by applicant]
WO WO2021173722A3
· 2021
[cited by applicant]
WO WO2022236221A1
· 2022
[cited by applicant]
Kurtz et al., “Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction”, Cell, vol. 178, No. 3, Jul. 25, 2019, pp. 699-713.
[cited by applicant]
Lawrence, MS et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 499(7457):214-218 (Jul. 11, 2013) Epub Jun. 16, 2013.
[cited by applicant]
Leary, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. Feb. 24, 2010;2(20):20ra14.
[cited by applicant]
Lewis et al., “Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center”, Cancer Epidemiology, Biomarkers & Prevention, vol. 24, No. 4, Apr. 1, 2015, pp. 664-6…
[cited by applicant]
Ley, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. Nov. 6, 2008;456(7218):66-72.
[cited by applicant]
Liao, G.J.W. et al., “Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles,” Clin. Chem. 2011, 57(1), 92-101.
[cited by applicant]
Liu et al., “Biological background of the genomic variations of cf-DNA in healthy individuals”, Annals of Oncology, vol. 30, No. 3, Mar. 1, 2019, pp. 464-470.
[cited by applicant]
Lui, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. Mar. 2002;48(3):421-427.
[cited by applicant]
Ma et al., “Annual Number of Lung Cancer Deaths Potentially Avertable by Screening in the United States”, Cancer, vol. 119, No. 7, Apr. 1, 2013, pp. 1381-1385.
[cited by applicant]
Martincorena et al. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell 171, 1029-1041 (Nov. 16, 2017). With Erratum.
[cited by applicant]
Mermel et al., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol, 12:R41 (2011).
[cited by applicant]
Mir, et al. Short Barcodes for Next Generation Sequencing. PLoS One. vol. No. 8, Issue No. 12, (2013): 8 Pages.
[cited by applicant]
Moss et al. Comprehensive Human Cell-Type Methylation Atlas Reveals Origins of Circulating Cell-Free DNA in Health and Disease. Nature Communications 9(1):5068 (2018).
[cited by applicant]
Mouliere et al. Enhanced Detection of Circulating Tumor DNA by Fragment Size Analysis. Science Translational Medicine 10(466):eaat4921 (2018).
[cited by applicant]
Newman et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. May 2014 ; 20(5): 548-554. With Supplementary Text and Figures (Supplementary Figures 1-8 and Supplemen…
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/455,209, Dated Apr. 18, 2022, 10 pgs.
[cited by applicant]
Office Action for U.S. Appl. No. 17/107,668, Dated Jun. 17, 2021, 27 pgs.
[cited by applicant]
Office Action for U.S. Appl. No. 17/107,668, Dated Oct. 21, 2021, 40 pgs.
[cited by applicant]
PCT/US2021/019478 International Search Report and Written Opinion dated Aug. 25, 2021.
[cited by applicant]
Pfeifer et al., “Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers”, Oncogene, vol. 21, No. 48, Oct. 15, 2002, pp. 7435-7451.
[cited by applicant]
Pinsky et al., “Performance of Lung-RADS in the National Lung Screening Trial: A Retrospective Assessment”, Annals of Internal Medicine, vol. 162, No. 7, Apr. 7, 2015, pp. 485-491.
[cited by applicant]
Pinsky et al., “The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology”, Cancer, vol. 119, No. 22, Nov. 15, 2013, pp. 3976-3983.
[cited by applicant]
Ptashkin et al., “Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors”, JAMA Oncology, vol. 4, No. 11, Nov. 1, 2018, pp. 1589-1593.
[cited by applicant]
Qian et al. A novel pathway-based approach improves lung cancer risk prediction using germline genetic variations. Cancer Epidemiol Biomarkers Prev. Aug. 2016 ; 25(8): 1208-1215.
[cited by applicant]
Response to Jun. 17, 2021 Office Action for U.S. Appl. No. 17/107,668, filed Sep. 17, 2021, 79 pgs.
[cited by applicant]
Response to Oct. 21, 2021 Office Action for U.S. Appl. No. 17/107,668, filed Apr. 21, 2022, 101 pgs.
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 17/107,668, Dated Apr. 26, 2021, 9 pgs.
[cited by applicant]
Roberts et al. Hypermutation in human cancer genomes: footprints and mechanisms. Nature Reviews Cancer, vol. 14, pp. 786-800 (2014).
[cited by applicant]
Saunders et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatic, 28(14):1811-1817 (2012).
[cited by applicant]
Serpas et al. Dnase1i3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. PNAS, vol. 116, No. 2, pp. 641-649 (Jan. 8, 2019). Published online Dec. 28, 2018.
[cited by applicant]
Shen et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579-83.
[cited by applicant]
Siegel et al. Cancer statistics, 2019. A Cancer Journal For Clinicians 69(1):7-34 (2019).
[cited by applicant]
Snyder et al., Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 164(1-2):57-68 (2016).
[cited by applicant]
Spindler et al. Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. Clin Cancer Res; 18(4) pp. 1177-1185 (Feb. 1…
[cited by applicant]
Steensma et al., “Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes”, Blood, vol. 126, No. 1, Jul. 2, 2015, pp. 9-16.
[cited by applicant]
Supplementary Information for Chabon et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. https://doi.org/10.1038/s41586-020-2140-0. Published online Mar. 25, 2020. 27 pages.
[cited by applicant]
Supplementary Note for Chabon et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. https://doi.org/10.1038/s41586-020-2140-0. Published online Mar. 25, 2020. 4 pages.
[cited by applicant]
Swanton et al., “Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study”, Journal o…
[cited by applicant]
Travis et al., “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma”, Journal of Thoracic O…
[cited by applicant]
Underhill et al. Fragment Length of Circulating Tumor DNA. Edited by David J. Kwiatkowski. PLOS Genetics 12(7):e1006162 (2016).
[cited by applicant]
U.S. Appl. No. 17/455,209 Notice of Allowance dated Aug. 2, 2022.
[cited by applicant]
U.S. Appl. No. 17/455,209 Notice of Allowance dated Jun. 13, 2022.
[cited by applicant]
U.S. Appl. No. 17/646,472 Office Action dated Aug. 29, 2022.
[cited by applicant]
U.S. Appl. No. 17/646,473 Notice of Allowance dated Jan. 13, 2023.
[cited by applicant]
U.S. Appl. No. 17/646,473 Notice of Allowance dated Nov. 9, 2022.
[cited by applicant]
U.S. Appl. No. 17/646,473 Office Action dated Jun. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/646,473 Office Action dated Oct. 17, 2022.
[cited by applicant]
U.S. Appl. No. 17/661,034 Notice of Allowance dated Jun. 2, 2023.
[cited by applicant]
U.S. Appl. No. 17/661,034 Office Action dated Feb. 2, 2023.
[cited by applicant]
U.S. Appl. No. 17/661,730 Notice of Allowance dated Jan. 12, 2023.
[cited by applicant]
U.S. Appl. No. 17/661,730 Office Action dated Aug. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/661,730 Office Action dated Dec. 1, 2022.
[cited by applicant]
U.S. Appl. No. 17/820,200 Office Action dated Apr. 26, 2023.
[cited by applicant]
U.S. Appl. No. 17/820,200 Office Action dated Aug. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/056,652 Notice of Allowance dated Sep. 14, 2023.
[cited by applicant]
U.S. Appl. No. 18/056,652 Office Action dated May 22, 2023.
[cited by applicant]
U.S. Appl. No. 18/056,656 Office Action dated Jul. 3, 2023.
[cited by applicant]
U.S. Appl. No. 18/056,656 Office Action dated Sep. 29, 2023.
[cited by applicant]
U.S. Appl. No. 18/167,803 Office Action dated Dec. 7, 2023.
[cited by applicant]
U.S. Appl. No. 18/167,804 Office Action dated Aug. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/172,957 Office Action dated Apr. 26, 2023.
[cited by applicant]
U.S. Appl. No. 18/172,957 Office Action dated Aug. 17, 2023.
[cited by applicant]
Vendrell et al. Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management. Int. J. Mol. Sci. 2017, 18, 264. 19 pages.
[cited by applicant]
Vodak et al., “Sample-Index Misassignment Impacts Tumour Exome Sequencing”, Scientific Reports, vol. 8, No. 5307, Mar. 28, 2018, 6 pgs.
[cited by applicant]
Wagle et al. High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing. Cancer Discov. Jan. 2012 ; 2(1): 82-93.
[cited by applicant]
Weissfeld et al. Lung cancer risk prediction using common SNPs located in GWAS-identified susceptibility regions. J Thorac Oncol. Nov. 2015 ; 10(11): 1538-1545.
[cited by applicant]
Wender et al., “American Cancer Society lung cancer screening guidelines”, CA: A Cancer Journal for Clinicians, vol. 63, No. 2, Mar./Apr. 2013, pp. 106-117.
[cited by applicant]
Xie et al., “Age-related mutations associated with clonal hematopoietic expansion and malignancies”, Nature Medicine, vol. 20, No. 12, Oct. 19, 2014, pp. 1472-1478.
[cited by applicant]
Young et al., “Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults”, Nature Communications, vol. 7, 12484, Aug. 22, 2016, 7 pgs.
[cited by applicant]
Papageorgiou et al., “Fetal-specific DNA methylation ratio permits non- invasive prenatal diagnosis of trisomy 21”, Nature Medicine, vol. 17, Mar. 6, 2011, pp. 510-513.
[cited by applicant]
Pasqualucci et al., “Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma”, Nature Genetics, vol. 43, Jul. 31, 2011, pp. 830-837.
[cited by applicant]
Pasqualucci et al., “Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas”, Nature, vol. 412, Jul. 19, 2001, pp. 341-346.
[cited by applicant]
Phallen et al., “Direct detection of early-stage cancers using circulating tumor DNA”, Science Translational Medicine, vol. 9, No. 403, Aug. 16, 2017, 12 pgs.
[cited by applicant]
Puente et al., “Non-coding recurrent mutations in chronic lymphocytic leukaemia”, Nature, vol. 526, Jul. 22, 2015, pp. 519-524.
[cited by applicant]
Qian et al., “B Cell Super-Enhancers and Regulatory Clusters Recruit AID Tumorigenic Activity”, Cell, vol. 159, Dec. 18, 2014, pp. 1524-1537.
[cited by applicant]
Reinert et al., “Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer”, JAMA Oncology, vol. 5, No. 8, May 9, 2019, pp. 1124-1131.
[cited by applicant]
Richter et al., “Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing”, Nature Genetics, vol. 44, Nov. 11, 2012, pp. 1316-1320.
[cited by applicant]
Robbiani et al., “AID Is Required for the Chromosomal Breaks in c-myc that Lead to c-myc/lgH Translocations”, Cell, vol. 135, No. 6, Dec. 12, 2008, pp. 1028-1038.
[cited by applicant]
Roschewski et al., “Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study”, The Lancet Oncology, vol. 16, No. 5, May 1, 2015, pp. 541-549.
[cited by applicant]
Rosenthal et al., “deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution”, Genome Biology, vol. 17, No. 31, Feb. 22, 2016, 11 pgs.
[cited by applicant]
Rowley, “Chromosome Studies in the Non-Hodgkin's Lymphomas: The Role of the 14;18 Translocation”, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 6, No. 5, May 1988, pp.…
[cited by applicant]
Scherer et al., “Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA”, Science Translational Medicine, vol. 8, No. 364, Nov. 9, 2016, 364ra155, 11 pgs.
[cited by applicant]
Scherer et al., “High-throughput sequencing for noninvasive disease detection in hematologic malignancies”, Blood, vol. 130, No. 4, Jul. 27, 2017, pp. 440-452.
[cited by applicant]
Schmitt et al., “Detection of ultra-rare mutations by next-generation sequencing”, Proceedings of the National Academy of Sciences, vol. 109, No. 36, Sep. 4, 2012, p. 14508-14513.
[cited by applicant]
Schmitz et al., “Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics”, Nature, vol. 490, Aug. 12, 2012, pp. 116-120.
[cited by applicant]
Schmitz et al., “Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma”, The New England Journal of Medicine, vol. 378, Apr. 12, 2018, pp. 1396-1407.
[cited by applicant]
Sozzi et al., “Analysis of Circulating Tumor DNA in Plasma at Diagnosis and during Follow-Up of Lung Cancer Patients”, Cancer Research, vol. 61, No. 12, Jun. 15, 2001, pp. 4675-4678.
[cited by applicant]
Steidl et al., “MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers”, Nature, vol. 471, Mar. 2, 2011, pp. 377-381.
[cited by applicant]
Sugimoto et al., “Improved Thermodynamic Parameters and Helix Initiation Factor to Predict Stability of DNA Duplexes”, Nucleic Acids Research, vol. 24, No. 22, Nov. 1, 1996, pp. 4501-4505.
[cited by applicant]
Thierry et al., “Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA”, Nature Medicine, vol. 20, Mar. 23, 2014, pp. 430-435.
[cited by applicant]
Tie et al., “Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer”, Science Translational Medicine, vol. 8, No. 346, Jul. 6, 2016, 10 pgs.
[cited by applicant]
Vaque et al., “B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies”, Haematologica, vol. 99, No. 2, Feb. 2014, pp. 222-231.
[cited by applicant]
Wang et al., “Diagnosis of Pneumocystis jirovecii pneumonia with serum cell-free DNA in non-HIV-infected immunocompromised patients”, Oncotarget, vol. 8, No. 42, Sep. 22, 2017, pp. 71946-71953.
[cited by applicant]
International Search Report and Written Opinion for International Application PCT/US2020/059526, Report Completed Jan. 22, 2021, Mailed Jan. 22, 2021, 21 pgs.
[cited by applicant]
“Pan-cancer analysis of whole genomes”, The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Nature, vol. 578, Feb. 5, 2020, pp. 82-93.
[cited by applicant]
Abbosh et al., “Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection”, Nature Reviews Clinical Oncology, vol. 15, Jul. 3, 2018, pp. 577-586.
[cited by applicant]
Abbosh et al., “Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution”, Nature, vol. 545, Apr. 26, 2017, pp. 446-451.
[cited by applicant]
Alexandrov et al., “Clock-like mutational processes in human somatic cells”, Nature Genetics, vol. 47, Nov. 9, 2015, pp. 1402-1407.
[cited by applicant]
Alexandrov et al., “Signatures of mutational processes in human cancer”, Nature, vol. 500, Aug. 14, 2013, pp. 415-421, doi:10.1038/nature 12477.
[cited by applicant]
Alexandrov et al., “The repertoire of mutational signatures in human cancer”, Nature, vol. 578, Feb. 5, 2020, pp. 94-101.
[cited by applicant]
Alizadeh, A et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling”, Nature, vol. 403, Feb. 3, 2000, pp. 503-511.
[cited by applicant]
Alkodsi et al., “Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes”, Leukemia, vol. 33, Jun. 11, 2019, pp. 2662-2672.
[cited by applicant]
Bell et al., “Chromosome-scale mega-haplotypes enable digital karyotyping of cancer aneuploidy”, Nucleic Acids Research, vol. 45, No. 19, Nov. 2, 2017, 13 pgs.
[cited by applicant]
Bettegowda et al., “Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies”, Science Translational Medicine, vol. 6, No. 224, Feb. 19, 2014, 11 pgs.
[cited by applicant]
Bianconi et al., “An estimation of the number of cells in the human body”, Annals of Human Biology, vol. 40, No. 6, Jul. 5, 2013, pp. 463-471.
[cited by applicant]
Bozdech et al., “Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray”, Genome Biology, vol. 4, No. R9, Jan. 31, 2003, 15 pgs.
[cited by applicant]
Brenner et al., “Next-generation sequencing diagnostics of bacteremia in sepsis (Next GeneSiS-Trial): Study protocol of a prospective, observational, noninterventional, multicenter, clinical trial”, Medicine, vol. 97, N…
[cited by applicant]
Burns et al., “Evidence for APOBEC3B mutagenesis in multiple human cancers”, Nature Genetics, vol. 45, Jul. 14, 2013, pp. 977-983.
[cited by applicant]
Chabon et al., “Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients”, Nature Communications, vol. 7, No. 11815, Jun. 10, 2016, 14 pgs.
[cited by applicant]
Chaudhuri et al., “Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling”, Cancer Discovery, vol. 7, No. 12, Dec. 2017, pp. 1394-1403.
[cited by applicant]
De Vlaminck et al., “Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection”, Science Translational Medicine, vol. 6, No. 241, Jun. 18, 2014, 8 pgs.
[cited by applicant]
De Vlaminck et al., “Noninvasive monitoring of infection and rejection after lung transplantation”, PNAS, vol. 112, No. 43, Oct. 27, 2015, pp. 13336-13341.
[cited by applicant]
De Yebenes et al., “Activation-induced deaminase: light and dark sides”, Trends in Molecular Medicine, vol. 12, No. 9, Sep. 1, 2006, pp. 432-439.
[cited by applicant]
Deng et al., “TNER: a novel background error suppression method for mutation detection in circulating tumor DNA”, BMC Bioinformatics, vol. 19, No. 387, Oct. 20, 2018, 7 pgs.
[cited by applicant]
Dewey et al., “Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence”, PLos Genetics, Sep. 15, 2011, vol. 7, Issue 9, 15 pgs.
[cited by applicant]
Diaz et al., “Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing”, PLoS One, vol. 11, No. 11, Nov. 10, 2016, 18 pgs.
[cited by applicant]
Diehl et al., “Circulating mutant DNA to assess tumor dynamics”, Nature Medicine, vol. 14, Jul. 31, 2008, pp. 985-990.
[cited by applicant]
Fan et al., “Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood”, Proceedings of the National Academy of Sciences USA, Oct. 21, 2008, vol. 105, No. 42, pp. 16266-16271.
[cited by applicant]
Garcia-Murillas et al., “Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer”, Science Translational Medicine, vol. 7, No. 302, Aug. 26, 2015, 11 pgs.
[cited by applicant]
Jaeger et al., “Improved predictions of secondary structures for RNA”, Proceedings of the National Academy of Sciences, vol. 86, No. 20, Oct. 1, 1989, pp. 7706-7710.
[cited by applicant]
Jiang et al., “Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients”, Proceedings of the National Academy of Sciences, vol. 112, No. 11, Feb. 2, 2015, pp. E1317-E1325.
[cited by applicant]
Kalinich et al., “Cancer detection: Seeking signals in blood”, Science, vol. 359, No. 6378, Feb. 23, 2018, pp. 866-867.
[cited by applicant]
Kennedy et al., “Detecting ultralow-frequency mutations by Duplex Sequencing”, Nature Protocols, vol. 9, Oct. 9, 2014, pp. 2586-2606.
[cited by applicant]
Khodabakhshi et al., “Recurrent targets of aberrant somatic hypermutation in lymphoma”, Oncotarget, vol. 3, No. 11, Nov. 2012, pp. 1308-1319.
[cited by applicant]
Kurtz, “Personalized Risk Assessment and Disease Monitoring in Non-Hodgkin Lymphoma from Circulating Tumor DNA”, ProQuest, Dec. 2017, 258 pgs.
[cited by applicant]
Kurtz et al., “Circulating Tumor DNA Measurements as Early Outcome Predictors in Diffuse Large B-Cell Lymphoma”, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 36, No. …
[cited by applicant]
Kurtz et al., “Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing”, Blood, vol. 125, No. 24, Jun. 11, 2015, pp. 3679-3687.
[cited by applicant]
Kurtz et al., “Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA”, Blood, vol. 134, Supp. 1, Nov. 13, 2019, pp. 552.
[cited by applicant]
Kurtz et al., “Reply to J. Wang et al.”, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 37, No. 9, Mar. 20, 2019, pp. 755-757.
[cited by applicant]
Lenz et al., “Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma”, The Journal of Experimental Medicine, vol. 204, No. 3, Mar. 19, 2007, p…
[cited by applicant]
Li et al., “Fast and accurate short read alignment with Burrows-Wheeler transform”, Bioinformatics, May 18, 2009, vol. 25, No. 14, pp. 1754-1760.
[cited by applicant]
Lieber, “Mechanisms of human lymphoid chromosomal translocations”, Nature Reviews Cancer, vol. 16, May 25, 2016, pp. 387-398.
[cited by applicant]
Lo et al., “Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal Plasma”, The New England Journal of Medicine, vol. 339, No. 24, Dec. 10, 1998, pp. 1734-1738.
[cited by applicant]
Lo et al., “Presence of fetal DNA in maternal plasma and serum”, The Lancet, vol. 350, Aug. 16, 1997, pp. 485-487.
[cited by applicant]
Lu et al., “BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements”, Blood, vol. 121, No. 22, May 30, 2013, pp. 4551-4554.
[cited by applicant]
Morin et al., “Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing”, Blood, vol. 122, No. 7, Aug. 15, 2013, pp. 1256-1265.
[cited by applicant]
Nakamura et al., “Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma”, Leukemia, vol. 15, Mar. 1, 2001, pp. 452-457.
[cited by applicant]
Neelapu et al., “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma”, The New England Journal of Medicine, vol. 377, No. 26, Dec. 28, 2017, pp. 2531-2544.
[cited by applicant]
Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage”, Nature Medicine, vol. 20, Apr. 6, 2014, pp. 548-554.
[cited by applicant]
Newman et al., “Integrated digital error suppression for improved detection of circulating tumor DNA”, Nature Biotechnology, vol. 34, Mar. 28, 2016, pp. 547-555.
[cited by applicant]
EP20240161425.4 Extended European Search Report dated Jul. 18, 2024.
[cited by applicant]
He Qian, et al. Application and research progress of second-generation sequencing technology in the diagnosis and treatment of solid tumors. Journal of Hebei Medical University, No. 12. Published Dec. 5, 2018. pp. 1483-…
[cited by applicant]
Jonsson et al. Data Descriptor: Whole genome characterization of sequence diversity of 15,220 Icelanders. Scientific Data 4:170115 (2017). 9 pages.
[cited by applicant]
Kurtz, David M. et al. Phased variants improve DLBCL minimal residual disease detection at the end of therapy. Hematological Oncology, Supplement: 16th International Conference on Malignant Lymphoma, Virtual Edition 39(…
[cited by applicant]
Mateo, et al. Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials. J Clinical Oncology. 30,…
[cited by applicant]
Personalized risk assessment and disease monitoring in non-Hodgkin lymphoma from circulating tumor DNA [electronic resource], Stanford University Library Searchworks Catalog, Retrieved from https://searchworks.stanford.…
[cited by applicant]
Submit Your Dissertation or Thesis. [Website] Stanford University, Stanford Student Services. Retrieved Jul. 16, 2024 from URL: https://studentservices.stanford.edu/my-academics/earn-my-degree/graduate-degree-progress/d…
[cited by applicant]
Tewhey et al., The importance of phase information for human genomics. Nat Rev Genet. 12(3):215-223 (2011).
[cited by applicant]
U.S. Appl. No. 18/056,656 Advisory Action dated Feb. 8, 2024.
[cited by applicant]
U.S. Appl. No. 18/056,656 Office Action dated Apr. 23, 2024.
[cited by applicant]
U.S. Appl. No. 18/167,803 Office Action dated Mar. 27, 2024.
[cited by applicant]
U.S. Appl. No. 18/167,804 Notice of Allowance dated Feb. 6, 2024.
[cited by applicant]
U.S. Appl. No. 18/167,804 Notice of Allowance dated Jan. 24, 2024.
[cited by applicant]
U.S. Appl. No. 18/435,880 Office Action dated Jul. 3, 2024.
[cited by applicant]
U.S. Appl. No. 18/481,092 Office Action dated Jul. 22, 2024.
[cited by applicant]
U.S. Appl. No. 18/481,092 Office Action dated Mar. 12, 2024.
[cited by applicant]
Willems, et al. Genome-wide profiling of heritable and de novo STR variations. Nat Methods. Jun. 2017;14(6):590-592. doi: 10.1038/nmeth.4267. Epub Apr. 24, 2017.
[cited by applicant]
Ardila et al., “End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography”, Nat. Med., Jun. 2019, vol. 25, No. pp. 954-961, published online May 20, 2019, doi: 10.1038/s…
[cited by applicant]
Bailey, et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173.2 (2018): 371-385.
[cited by applicant]
Ballenghien et al., “Patterns of cross-contamination in a multispecies population genomic project: detection, quantification, impact, and solutions”, BMC Biology, vol. 15, No. 25, Mar. 29, 2017, 16 pgs.
[cited by applicant]
Bandelt et al., “Contamination and sample mix-up can best explain some patterns of mtDNA instabilities in buccal cells and oral squamous cell carcinoma”, BMC Cancer, vol. 9, No. 113 Apr. 16, 2009, 8 pgs.
[cited by applicant]
Bentley et al., “Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry,” Nature, 456(7218): 53-59 (2008).
[cited by applicant]
Cancer Genome Atlas Research Network, “Comprehensive genomic characterization of squamous cell lung cancers,” Nature, 489, 519-525 (2012).
[cited by applicant]
“Carter et al., “Absolute quantification of somatic DNA alterations in human cancer,” Nat Biotechnol, 30:413-21 (2012).”.
[cited by applicant]
Chan, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. Jan. 2013;59(1):21…
[cited by applicant]
Chaudhuri et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DnA Profiling. Cancer Discov; 7(12); 1394-403 (2017). With Supplemental Tables Table of Contents and Table S6.
[cited by applicant]
Chen et al., “AfterQC: automatic filtering, trimming, error removing and quality control for fastq data”, BMC Bioinformatics, vol. 18, Suppl. 3, Mar. 14, 2017,10 pgs.
[cited by applicant]
Chicard et al. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clin Cancer Res; 24(4); 939-49 (2017).
[cited by applicant]
Chiu et al. cfDNA screening and diagnosis of monogenic disorders—where are we heading? Prenatal Diagnosis 2018, 38, 52-58.
[cited by applicant]
Church et al., “Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer”, The National Lung Screening Trial Research Team, The New England Journal of Medicine, vol. 368, No. 21, May 23, 2013, pp. 1980…
[cited by applicant]
Cohen et al., Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 359(6378):926-930 (2018).
[cited by applicant]
“Comprehensive molecular profiling of lung adenocarcinoma”, The Cancer Genome Atlas Research Network, Nature, vol. 511, Jul. 31, 2014, pp. 543-550.
[cited by applicant]
Co-pending Mexico Application No. MX/A/2022/005588, inventors Kurtz; David M. et al., filed on May 6, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 18/167,804, inventors Kurtz; David M. et al., filed on Feb. 10, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/452,463, inventors Chabon; Jacob J. et al., filed Aug. 18, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/481,092, inventors Kurtz; David M. et al., filed Oct. 4, 2023.
[cited by applicant]
Corcoran et al., “Application of Cell-free DNA Analysis to Cancer Treatment”, The New England Journal of Medicine, vol. 379, pp. 1754-1765 (2018).
[cited by applicant]
Costello, et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. Apr. 1, 2013;41(6):e67…
[cited by applicant]
Cristiano et al. Genome-Wide Cell-Free DNA Fragmentation in Patients with Cancer. Nature 570 (7761):385-389. (Jun. 2019).
[cited by applicant]
Dai et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. The Lancet, vol. 7, Issue 10, pp. 881-891 (Oct. 2019).
[cited by applicant]
De Koning et al., “PL02.05 Effects of vol. CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial”, Journal of Thoracic Oncology, vol. 13, No. 10, Supplement, Oct. 2018, p…
[cited by applicant]
Denissenko et al., “Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53”, Science, vol. 274, No. 5286, Oct. 18, 1996, pp. 430-432.
[cited by applicant]
Diaconis et al., “Methods for Studying Coincidences”, Journal of the American Statistical Association, vol. 84, No. 408, Dec. 1989, pp. 853-861.
[cited by applicant]
Dissertations and theses, Stanford Libraries, Special Collections & University Archives website, accessed on Jun. 21, 2021, available online at: https://library.stanford.edu/spc/university-archives/dissertations-and-the…
[cited by applicant]
Doria-Rose et al., “Use of Lung Cancer Screening Tests in the United States: Results from the 2010 National Health Interview Survey”, Cancer Epidemiology, Biomarkers & Prevention, vol. 21, No. 7, Jul. 1, 2012, pp. 1049-…
[cited by applicant]
Dou et al., “Detecting Somatic Mutations in Normal Cells”, Trends Genet. Jul. 2018, 34(7): 545-557. doi:10.1016/j.tig.2018.04.003.
[cited by applicant]
EP20885631.0 Extended European Search Report dated Sep. 27, 2023.
[cited by applicant]
Ersek et al., “Knowledge of, Attitudes Toward, and Use of Low-Dose Computed Tomography for Lung Cancer Screening Among Family Physicians”, Cancer, vol. 122, No. 15, Aug. 1, 2016, pp. 2324-2331.
[cited by applicant]
Forshew, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. May 30, 2012;4(136):136ra68.
[cited by applicant]
Genovese et al., “Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence”, The New England Journal of Medicine, vol. 371, Dec. 25, 2014, pp. 2477-2487.
[cited by applicant]
Goldstraw et al., “The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer”, Journal of Thoracic Oncology, v…
[cited by applicant]
Gregory et al. Targeted single molecule mutation detection with massively parallel sequencing. Nucleic Acids Research, 2016, vol. 44, No. 3 e22. Published online Sep. 17, 2015. 11 pages.
[cited by applicant]
Hainaut et al., “Somatic TP53 Mutations in the Era of Genome Sequencing”, Cold Spring Harbor Perspectives in Medicine, vol. 6, No. 11, Nov. 2016, 22 pgs.
[cited by applicant]
Han, et al. The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet. Feb. 6, 2020;106(2):202-214. doi: 10.1016/j.ajhg.2020.01.008. Epub Jan. 30, 2020.
[cited by applicant]
Hawkins et al. Indel-correcting DNA barcodes for high-throughput sequencing. PNAS, vol. 115, No. 27 (E6217-E6226) (Published online Jun. 20, 2018).
[cited by applicant]
Hu et al., “False-Positive Plasma Genotyping Due to Clonal Hematopoiesis”, Clinical Cancer Research, vol. 24, No. 18, Sep. 15, 2018, pp. 4437-4443.
[cited by applicant]
Imperiale, et al., Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. Apr. 2014; 370:1287-1297.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/059526, Report issued May 10, 2022, Mailed May 19, 2022, 09 Pgs.
[cited by applicant]
International Preliminary Report on Patentability for International Application PCT/US2021/019478, Report issued Aug. 30, 2022, Mailed on Sep. 9, 2022, 10 Pgs.
[cited by applicant]
International Preliminary Report on Patentability for International Application PCT/US2021/019481, Report issued Aug. 30, 2022, Mailed on Sep. 9, 2022, 9 Pgs.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/019481, Search completed Jun. 11, 2021, Mailed Jul. 15, 2021, 19 Pgs.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/071759, search completed Jun. 6, 2022, Mailed Jun. 29, 2022, 13 Pgs.
[cited by applicant]
Invitation to Pay Add'l Fees and Partial Search Rpt Rcvd for International Application PCT/US2020/059526, Mailed Dec. 15, 2020, 2 Pages.
[cited by applicant]
Jaiswal et al., “Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes”, The New England Journal of Medicine, vol. 371, No. 26, Dec. 25, 2014, pp. 2488-2498.
[cited by applicant]
Jemal et al., Lung cancer screening with low-dose computed tomography in the United States—2010 to 2015. JAMA Oncol. 3(9):1278-1281 (2017).
[cited by applicant]
Jensen et al., “Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)”, Centers for Medicare & Medicaid Services, CAG-00439N, Retrieved from: https://www.cms.gov/medicare-coverage-database…
[cited by applicant]
Kandoth et al., “Mutational landscape and significance across 12 major cancer types,” Nature, 502:333-339 (2013).
[cited by applicant]
Karczewski et al., “Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes”, bioRxiv, doi: 10.1101/531210, Aug. 13, 2019, 44 pgs.
[cited by applicant]
Kinde et al. Detection and quantification of rare mutations with massively parallel sequencing. PNAS, vol. 108, No. 23, pp. 9530-9535 (Jun. 7, 2011). With Supporting Information (10 pages).
[cited by applicant]
Kircher et al., Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform, Nucleic Acids Res., 40(1): e3 (8 pages) (2012).
[cited by applicant]
Kucab et al., “A Compendium of Mutational Signatures of Environmental Agents”, Cell, vol. 177, No. 4, May 2, 2019, pp. 821-836.e16.
[cited by applicant]
Castel, Stephane E. et al. Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. Nat Genet. Sep. 2018;50(9):1327-1334. doi: 10.1038/s41588-018-0192-y. Epub Aug. 20, 2018.
[cited by applicant]
EP20220799768.1 Extended European Search Report dated Oct. 11, 2024.
[cited by applicant]
Gorelick, Alexander N et al. Phase and context shape the function of composite oncogenic mutations. Nature. Jun. 2020;582(7810):100-103. doi: 10.1038/s41586-020-2315-8. Epub May 27, 2020.
[cited by applicant]
Illumina et al. Local Run Manager TruSight Oncology 500 Analysis Module. Workflow Guide. Nov. 27, 2019. Retrieved from the Internet: URL: https://jp.support.illumina.com/content/dam/illumina-support/documents/downloads/…
[cited by applicant]
U.S. Appl. No. 18/435,880 Office Action dated Sep. 27, 2024.
[cited by applicant]
Zhang, et al. “Haplotype phasing of whole human genomes using bead-based barcode partitioning in a single tube.” Nature biotechnology 35.9 (2017): 852.
[cited by applicant]
Librarian view of catalog entry for “Personalized risk assessment and disease monitoring in non-Hodgkin lymphoma from circulating tumor DNA, David Kurtz”, Date catalogued: Dec. 11, 2017, Accessed on Aug. 19, 2021, 2 pgs.
[cited by applicant]
“Copyright Reminder: Dissertations”, Stanford Libraries, Retrieved from https://library.stanford.edu/using/copyright-reminder/common-situations/dissertations on Aug. 18, 2021, 2 pgs.
[cited by applicant]
“Dissertations and theses”, Stanford Libraries, Robin Li and Melissa Ma Science Library, Retrieved from https://library.stanford.edu/science/collections/chemistry-and-chemical-engineering-collection/dissertations-and-th…
[cited by applicant]
“Dissertations and theses”, Stanford Libraries, Special Collections & University Archives, Retrieved from https://library.stanford.edu/using/copyright-reminder/common-situations/dissertations on Jun. 21, 2021, 3 pgs.
[cited by applicant]
“eDissertation Requirements for Submission”, Stanford University Registrar's Office: Student Affairs Website, Retrieved from https://registrar.stanford.edu/students/dissertation-and-thesis-submission/preparing-dissertat…
[cited by applicant]
“Embargo and Restriction Options”, ProQuest, Retrieved from https://support.proquest.com/articledetail?id=kA0400000004JJCCA2 on Sep. 15, 2021, 4 pgs.
[cited by applicant]
“Format Requirements for eDissertation”, Stanford University Registrar's Office: Student Affairs Website, Retrieved from https://registrar.stanford.edu/students/dissertation-and-thesis-submission/preparing-dissertations…
[cited by applicant]
“Permission to publish”, Stanford Libraries, Special Collections & University Archives, Retrieved from https://library.stanford.edu/spc/using-our-collections/permission-publish on Aug. 30, 2021, 3 pgs.
[cited by applicant]
“Reading room policies & procedures”, Stanford Libraries, Special Collections & University Archives, Retrieved from https://library.stanford.edu/spc/using-our-collections/reading-room-policies-procedures on Jul. 30, 202…
[cited by applicant]
“Special policies: Guidelines to counsel & researchers seeking discovery from Stanford Libraries”, Stanford Libraries, Retrieved from https://library.stanford.edu/using/special-policies/guidelines-counsel-researchers-se…
[cited by applicant]
“Using our collections”, Stanford Libraries, Special Collections & University Archives, Retrieved from https://library.stanford.edu/spc/using-our-collections on Aug. 19, 2021, 3 pgs.
[cited by applicant]
Abbosh et al., “Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study”, Cancer Research, Proceedings of AACR Annual Meeting on Apr. 27-28, 20…
[cited by applicant]
Cibulskis et al., “Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples”, Nature Biotechnology, vol. 31, Feb. 10, 2013, pp. 213-219.
[cited by applicant]
Kim et al., “Strelka2: fast and accurate calling of germline and somatic variants”, Nature Methods, vol. 15, Jul. 16, 2018, pp. 591-594.
[cited by applicant]
Koboldt et al., “VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing”, Genome Research, Feb. 2, 2012, vol. 22, pp. 568-576, www.genome.org/cgi/doi/10.1101/gr.129684.111.
[cited by applicant]
Kurtz et al., “Methods and Systems for Analyzing Nucleic Acid Molecules”, U.S. Appl. No. 17/308,958, filed May 5, 2021, 434 pgs.
[cited by applicant]
Van Der Auwera et al., “From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline”, Current Protocols in Bioinformatics, vol. 43, No. 1110, Oct. 15, 2013, pp. 11.10.1-11.10.33…
[cited by applicant]
Kurtz, David M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39:1537-1547 (2021).
[cited by applicant]